Deep brain stimulation (DBS) remains a cornerstone of advanced Parkinson's disease therapy. MDS 2026 showcases significant advances in surgical techniques, targeting, device technology, and programming strategies.
Targets for Parkinson's Disease
flowchart TD
events_mds_2026_deep_brain_sti["Deep Brain Stimulation Updates MDS 2026"]
events_mds_2026_deep_brain_sti["remains"]
events_mds_2026_deep_brain_sti -->|"related to"| events_mds_2026_deep_brain_sti
style events_mds_2026_deep_brain_sti fill:#81c784,stroke:#333,color:#000
events_mds_2026_deep_brain_sti["cornerstone"]
events_mds_2026_deep_brain_sti -->|"related to"| events_mds_2026_deep_brain_sti
style events_mds_2026_deep_brain_sti fill:#81c784,stroke:#333,color:#000
events_mds_2026_deep_brain_sti["advanced"]
events_mds_2026_deep_brain_sti -->|"related to"| events_mds_2026_deep_brain_sti
style events_mds_2026_deep_brain_sti fill:#81c784,stroke:#333,color:#000
events_mds_2026_deep_brain_sti["Parkinson"]
events_mds_2026_deep_brain_sti -->|"related to"| events_mds_2026_deep_brain_sti
style events_mds_2026_deep_brain_sti fill:#81c784,stroke:#333,color:#000
style events_mds_2026_deep_brain_sti fill:#4fc3f7,stroke:#333,color:#000
Subthalamic Nucleus (STN)
- Most common target for PD in most centers
- Benefits: Significant reduction in levodopa dose (50-70%), motor symptoms
- Considerations: May worsen speech, cognition, mood
...Deep brain stimulation (DBS) remains a cornerstone of advanced Parkinson's disease therapy. MDS 2026 showcases significant advances in surgical techniques, targeting, device technology, and programming strategies.
Targets for Parkinson's Disease
Mermaid diagram (expand to render)
Subthalamic Nucleus (STN)
- Most common target for PD in most centers
- Benefits: Significant reduction in levodopa dose (50-70%), motor symptoms
- Considerations: May worsen speech, cognition, mood
Globus Pallidus Internus (GPi)
- Alternative target gaining popularity
- Benefits: Better dyskinesia control, fewer cognitive/behavioral side effects
- Considerations: Slightly less medication reduction than STN
Pedunculopontine Nucleus (PPN)
- Experimental target for gaitFreeze and axial symptoms
- Early results show modest benefit
- Ongoing studies investigate optimal parameters
Surgical Advances
Image-Guided Targeting
- High-resolution MRI — 7T MRI for precise anatomy
- Diffusion tensor imaging (DTI) — Visualize white matter tracts
- Intraoperative CT — Verify lead location
- MER integration — Microelectrode recording confirmation[@dbs2026]
Minimally Invasive Approaches
- Lead implantation accuracy — ±0.5mm with frame-based systems
- Asleep DBS — General anesthesia with image guidance
- frameless systems — Increased patient comfort
Device Technology
###Directional Leads
- segmented electrodes — Current steering in 3D
- Benefits: Customize stimulation, reduce side effects
- Data from MDS 2026: 30% improvement in therapeutic window
Closed-Loop Systems
- Adaptive DBS — Responsive to neural biomarkers
- Sensing capabilities — Local field potential monitoring
- VPED algorithm — Automated programming based on patient state
New Pulse Generators
- Smaller profiles — Less visible
- Longer battery life — Up to 15-20 years with rechargeable
- MR conditional — Safe for MRI scanning
Programming Innovations
Interleaving Stimulation
- Multiple programs — Different frequencies on different contacts
- Benefits: Optimize different symptoms (tremor, bradykinesia, dyskinesia)
Novel Parameter Settings
- High-frequency (130-180 Hz) — Standard for PD
- Low-frequency (60-80 Hz) — May help gaitFreeze
- Battery-efficient settings — Reduce device replacement
Personalized Approaches
- Symptom-specific programming — Based on patient presentation
- Machine learning — Optimize parameters algorithmically
- Remote programming — Telemedicine for adjustments
Clinical Outcomes
Motor Symptoms
| Outcome | STN DBS | GPi DBS |
|---------|---------|---------|
| UPDRS III (off-med) | 50-60% improvement | 40-50% improvement |
| On time | +4-6 hours/day | +3-5 hours/day |
| Levodopa reduction | 50-70% | 20-40% |
| Dyskinesia reduction | 70-90% | 80-90% |
Quality of Life
- PDQ-39: 30-50% improvement
- Activities of daily living: Significant improvement
- Caregiver burden: Reduced
Complications and Management
Surgical Complications
- Intracranial hemorrhage: 1-2% (often asymptomatic)
- Infection: 3-5%
- Hardware complications: 5-10%
- Speech disturbances: 10-30%
- Cognitive decline: 5-15%
- Mood changes: 5-10%
- Dysarthria: Controllable with programming
Future Directions
MDS 2026 highlights emerging research:
Gene therapy combined with DBS — Synergistic effects
Biomarker-responsive stimulation — Automation based on clinical state
DBS for prodromal PD — Early intervention
Network-based targeting — Personalized connectome approachesCross-Links
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Subthalamic Nucleus in Movement](/cell-types/subthalamic-nucleus-movement)
- [Globus Pallidus in Movement](/cell-types/globus-pallidus-externus-movement)
- [Technologies/Deep Brain Stimulation](/technologies/deep-brain-stimulation-parkinsons)
References
Unknown, DBS Surgical Techniques - MDS 2026 (2026) (2026)
[Unknown, STN vs GPi DBS Comparison (2024) (2024)](https://doi.org/10.1002/mds.294)
[Unknown, Directional DBS Outcomes (2025) (2025)](https://doi.org/10.1002/mds.297)